Hello and happy hump day, readers.
We had some breaking/exclusive news this morning on the digital health front: Dr. Toby Cosgrove, the former CEO of (and current adviser to) the renowned Cleveland Clinic, has joined the board of telemedicine startup Hims & Hers.
I spoke with Cosgrove and Hims & Hers chief Andrew Dudum ahead of the official announcement. The logic behind the pairing seems fairly clear—Cosgrove is a digital health evangelist with decades of experience in the provider and business sides of medicine, and Dudum is planning a significant expansion of his company’s virtual care services.
“I’d like to see them continue to expand their repertoire of services, we’ve had discussions on how you can do that,” Cosgrove tells Fortune. “Smoking cessation, weight reduction, etc.” He also wants to help the company develop relationships with (or, well, wrangle) regulators in Washington.
You can read my full writeup here.
Read on for the day’s news.
Sy Mukherjee, @the_sy_guy, sayak.mukherjee@fortune.com
DIGITAL HEALTH
Former Juul exec alleges the company knew it shipped tainted products. A former Juul executive has claimed that the vaping giant knowingly shipped tainted nicotine pods to customers. Juul strongly denies those claims, calling them "baseless" and essentially dismissing the former executive, who was fired earlier this year. (Fortune)
INDICATIONS
Biogen, Alkermes win MS drug approval. As Biogen plows forward with a risky—and ambitious—quest to receive the first-ever FDA approval for a disease-modifying Alzheimer's drug, the company (and partner Alkermes) got the green light from regulators on a multiple sclerosis treatment called Vumerity. Biogen shares were up about 2% in after-hours trading.
REQUIRED READING
Air Quality Monitors Are Quickly Becoming 2019's Must-Have Gadget, by Jennifer Alsever
Europe Is Starting to Declare Its Cloud Independence, by David Meyer
Stitch Fix Is Diving Into Data for a More Tailored Experience, by Phil Wahba
Find past coverage. Sign up for other Fortune newsletters.
